FDAnews Drug Daily Bulletin

Nov. 8, 2012 | Vol. 9 No. 220

Titan Files NDA for Slow-Release Anti-Opioid Probuphine

Titan Pharmaceutical has submitted an NDA seeking priority review of its Probuphine subcutaneous implant to treat adult opioid dependence. The product is designed to deliver buprenorphine HCl in a span of six months to reduce patients’ use of illicit drug. It uses the company’s ProNeura technology, a solid rod made from a mixture of ethylene-vinyl acetate and the drug substance.
Washington Drug Letter

Register Now
Print This Page
Email This Article
RSS
Archives

FDA Rejects Endo Petition To Deny Opana Generics FDA to Focus on HIV in Next Patient-Focused Drug Development Meeting FDA Hydrocodone Decision Delay Reflects Enforcement, Access Tensions FDA Rejects Endo’s Petition to Deny Generics of Opana ER

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.